Sartorius Stedim Biotech SA

As of June 30, 2026, Sartorius Stedim Biotech SA carries a market capitalization of 17.58B, placing it among publicly traded companies globally. Its enterprise value stands at 19.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sartorius Stedim Biotech SA's next confirmed earnings release is scheduled for January 28, 2027.

As of June 30, 2026, Sartorius Stedim Biotech SA has 97.29M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Sartorius Stedim Biotech SA maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sartorius Stedim Biotech SA recorded 94.40M in income tax expense.

As of the close on October 22, 2026, Sartorius Stedim Biotech SA's stock has gained approximately 0.75% over the past 52 weeks. The 50-day moving average sits at 201.33, while the 200-day moving average is 182.81.

As of June 30, 2026, Sartorius Stedim Biotech SA holds 232.80M in cash and equivalents against 2.40B in total debt, resulting in a net debt position of 2.03B. Total book value stands at 4.24B, with working capital of 186.20M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sartorius Stedim Biotech SA paid dividends of - - per share. Total shareholder yield reaches 5.05, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sartorius Stedim Biotech SA shareholders.

Sartorius Stedim Biotech SA's most recent stock split took place on May 6, 2016 with a 1:6 split ratio.